Korro Bio, Inc. (NASDAQ:KRRO) CFO Vineet Agarwal Sells 800 Shares

Korro Bio, Inc. (NASDAQ:KRRO) CFO Vineet Agarwal sold 800 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $70.00, for a total transaction of $56,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Vineet Agarwal also recently made the following trade(s):

• On Thursday, October 17th, Vineet Agarwal sold 10,216 shares of Korro Bio stock. The stock was sold at an average price of $78.26, for a total value of $799,504.16.

Korro Bio Price Performance

Korro Bio stock opened at $65.14 on Wednesday. The company’s 50 day simple moving average is $49.10 and its 200-day simple moving average is $46.85. Korro Bio, Inc. has a 1 year low of $30.00 and a 1 year high of $98.00.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($2.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.39) by ($0.04). Analysts predict that Korro Bio, Inc. will post -10.02 earnings per share for the current fiscal year.

Institutional Trading of Korro Bio

A number of large investors have recently modified their holdings of KRRO. Brown Brothers Harriman & Co. purchased a new stake in Korro Bio during the 2nd quarter worth about $28,000. Quest Partners LLC increased its stake in shares of Korro Bio by 172.1% during the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock worth $59,000 after buying an additional 1,124 shares during the period. Lynx1 Capital Management LP acquired a new stake in Korro Bio in the second quarter valued at approximately $129,000. Rhumbline Advisers purchased a new position in Korro Bio in the second quarter worth approximately $279,000. Finally, Atlas Venture Life Science Advisors LLC grew its holdings in Korro Bio by 1.6% during the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock worth $38,515,000 after acquiring an additional 17,857 shares in the last quarter. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on KRRO shares. William Blair assumed coverage on Korro Bio in a research note on Wednesday, August 14th. They issued an “outperform” rating and a $180.00 target price for the company. HC Wainwright lifted their target price on shares of Korro Bio from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Raymond James assumed coverage on shares of Korro Bio in a research note on Monday, October 21st. They issued a “strong-buy” rating and a $153.00 price target for the company. Finally, Royal Bank of Canada lifted their price target on shares of Korro Bio from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Monday, October 21st. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $142.17.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).